Creating Everyday Medical Heroes on the Northshore

Ochsner Cancer Research Trial Participation Closer to Home for Northshore Residents

Medical heroes can be found in everyday places because each day millions of Americans take part in clinical research trials that help develop new medical treatments. Ochsner is inviting Northshore residents to join in the fight by making clinical research trials available in physician’s offices in Covington and Slidell. As a member of the Louisiana Cancer Research Consortium (LCRC), Ochsner carries out a large number of cooperative research trials with cancer patients to find out whether promising approaches to cancer prevention, diagnosis, and treatment are safe and effective. These cancer clinical trials are all NIH (National Institutes of Health) approved and are for all major types of cancer. Participation in clinical research trials is strictly voluntary, must be approved by a patient’s doctor, and the patient must meet all of the trial criteria.  

“Clinical trials are the basis for discovering new treatments and cures for the diseases that affect so many of our loved ones. Ochsner Northshore is proud to offer local residents the chance to make a difference in their friends and family’s lives,” says Dr. Greg Bizette, of Ochsner Cancer Services on the North Shore.

The Ochsner Cancer Institute is committed to making cancer care more easily available to all Americans and to finding ways to receive comfortable treatment without hospitalization. The more people that take part in cancer clinical trials, the faster we will find better ways to treat cancer. Patients and family members—ask your doctors.

Below is a list of the clinical research trials that will be available to Ochsner Northshore patients, providing they meet all medical requirements:

• Breast Cancer - (E5103) To find out the disease-free survival of patients with lymph node positive & high risk lymph node negative breast cancer.

(PACCT-1) – Designed to validate the use of genetic testing to decide if a patient needs therapy for early stage breast cancer and to guide selection of the correct therapy when indicated.

• Colon Cancer (E5202) - To show an improvement in 3-year disease free survival for high-risk, stage II colon cancer patients.

• Lung - NSCLC - (E1505) To evaluate the survival rate of patients with Non-Small Cell Lung Cancer who are treated with chemotherapy.

Pancreas (N064B) - To find out whether adding dual-epidermal growth factor receptor (EGFR) inhibition to standard chemotherapy results in an improvement in overall survival in patients with untreated, metastatic pancreatic adenocarcinoma.

•  
• Cancer Control/Prevention (S0702) - To determine the rate of osteonecrosis of the jaw in cancer patients with bone metastasis receiving zoledronic acid treatment.
• CALGB (70604) - For patients with metastatic breast or prostate cancer, or multiple myeloma, to determine if receiving zoledronic acid therapy every 12-wks is better or worse than receiving therapy every 4-wks.
• Adjuvant therapies use drugs that have few or no effects by themselves, but may increase the effects of other drugs when given together. They are often included in vaccines to help the recipient's immune system.